{"groups":[{"description":"PCI-32765 420 mg per day\n\nPCI-32765","id":"FG000","title":"PCI-32765 420 mg Per Day"},{"description":"PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week\n\nPCI-32765\n\nDexamethasone","id":"FG001","title":"PCI-32765 560 mg Per Day, 40 mg Dexamethasone"},{"description":"PCI-32765 840 mg per day\n\nPCI-32765","id":"FG002","title":"PCI-32765 840 mg Per Day"},{"description":"PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week\n\nPCI-32765\n\nDexamethasone","id":"FG003","title":"PCI-32765 840 mg Per Day, 40 mg Dexamethasone"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"18"},{"comment":"Simon 2-stage design - cohort 4 expansion per stage 1 data (≥3 Clinical Benefit Responders observed","groupId":"FG003","numSubjects":"43"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"18"},{"groupId":"FG003","numSubjects":"43"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Simon 2-stage design . Stage 1 -13 subjects enrolled in cohort 1. For cohort 2,3, and 4, up to 18 subjects were enrolled in Stage 1. Cohort 4 was selected for expansion for enrollment of 43 subjects in Stage 2."}